Skip to main content
. 2020 Feb 3;12(2):121. doi: 10.3390/pharmaceutics12020121

Figure 6.

Figure 6

In vivo therapeutic efficacy of ABN401 in NSCLC patient-derived xenograft (PDX) models. (a) Growth curves of LU0858 NSCLC tumors in ABN401 and/or erlotinib-treated mice. Dose-dependent anti-tumor activity of ABN401 and in vivo anti-tumor activity of erlotinib alone or in combination with ABN401 is shown. P-values: *** < 0.001. (b) Tumor growth inhibition values on day 21 are shown.